Why would the EU be tougher than dealing with hundreds of individual insurers across the US? Don't forget Amarin fumbled the US too. Bad tiering, lack of coverage, State to State differences, etc.
ramfan...If/when China grants regulatory approval to Vascepa, Amarin will have some business advantages over other manufacturers of EPA.
i.e. Amarin will have a head start, since they are already marketing Vascepa in the U.S., in Europe and in the ROW...This means Amarin will be able to buy larger volumes of EPA than any other manufacturers...This will allow Amarin to request and receive lower prices for their purchases of API while still maintaining profitability.
News 
Market Data 
Discover 
AI
